<?xml version="1.0" encoding="UTF-8" standalone="no"?><information><Cell><NavigationPath><Head00>Adverse event</Head00><Stub><SubHeader0>Nonhaematologic toxicity</SubHeader0><StubValue>â€ƒElevated ALP</StubValue></Stub><HeaderValue>No. patients (%) Grade 4</HeaderValue></NavigationPath><value>0 (0)</value><CellType>Partially Numeric</CellType></Cell><Table><tableName>Major toxicities associated with gefitinib treatment</tableName><TableType>Subheader</TableType><tableOrder>Table 4</tableOrder><tableFooter>Abbreviations: ILD=interstitial lung disease; ALP=alkaline phosphatase; AST/ALT=aspartate aminotransferase/alanine aminotransferase.</tableFooter></Table><Document><DocumentTitle>A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations</DocumentTitle><PMC>2360715</PMC></Document></information>